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Abstract
Background-Sulindac, a non-steroidal anti-inflammatory drug, causes regression of colorectal adenomas in patients with familial adenomatous polyposis (FAP) Dependent and independent variables Per cent change from baseline number of polyps after treatment with sulindac for three months was evaluated with respect to nine clinical factors (Table I) : age (<v¢30 years old); sex; body weight (<v:65 kg); dose of sulindac (dose of sulindac prescribedxper cent of drug taken during the first three months per kg; <v-4.0 mg/kg/day); surgical status (subtotal colectomy or no prior colectomy); presence or absence of APC gene mutation as assessed by in vitro synthesised protein assay and by cloning and sequencing the entire coding region of the APC gene, as described previously9 11; presence or absence of extracolonic lesions (cutaneous cysts, osteomas, pigmented ocular fundus lesions, occult radioopaque jaw lesions, odontomas, extracolonic cancers and desmoids); number of polyps at baseline (<v¢20 polyps), and mean size of polyps at baseline (<v¢3.0 mm).
Statistical analysis
Polyp number and mean size were calculated before and after sulindac treatment, and differences were analysed for statistical significance by paired t test. Regression was expressed as per cent of base line.
The relation between change in per cent of baseline polyp number at three months (dependent variable) and patient clinical features (independent variables) was evaluated by both univariate and multivariate analysis and tested for significance by a t test. The contributions of independent variables found to have a significant impact on polyp regression by univariate analysis were evaluated by multiple regression analysis with per cent change from baseline number of polyps as the primary statistical outcome variable. Statistical significance was defined as p value <005. Table I shows the baseline clinical features of the study population. After three months of sulindac, polyp number had decreased to 45 per cent of baseline (Figure) and polyp size to 50 per cent of baseline (p<0.001 and p<Q001, respectively).
Results
Univariate analysis showed a significantly better polyp regression in older patients (p= 0004), those with previous subtotal colectomy and ileorectal anastomosis (p=0-001), and was borderline significant for patients without identified APC gene mutation (p=0.05). With multivariate regression analysis, only previous surgery (patients with colectomy and ileorectal anastomosis) was associated with statistically significant better polyp regression (Table II) . Analysis with polyp size as the dependent variable showed similar results (data not shown).
Discussion
Our finding of greater polyp regression in patients with retained rectum after subtotal colectomy compared with intact colon could Several clinical implications can be drawn from this analysis albeit with caution given the sample size of our study. Firstly, sulindac seems most effective for the treatment of adenomas in FAP patients with colectomy and ileorectal anastomosis, not for FAP patients without previous colon surgery. Thus, prophylactic colectomy will probably remain the primary treatment for patients with FAP. Secondly, large numbers of adenomas in the retained rectum should not be a deterrent to treatment. Caution should be applied, however, in those patients with rectal polyps of advanced histopathology or larger size than evaluated in this study. Also, although sulindac promotes polyp regression, efficacy in cancer prevention is another matter to be determined by longterm studies, especially in view of past case reports of rectal cancer in patients taking this drug.21 22 Consequently, sulindac treatment of patients with retained rectum should be coupled with vigilant endoscopic surveillance.
